David Altarac
Chief Tech/Sci/R&D Officer at ENTASIS THERAPEUTICS HOLDINGS INC.
David Altarac active positions
Companies | Position | Start | End |
---|---|---|---|
ENTASIS THERAPEUTICS HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 03/11/2019 | - |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 03/11/2019 | - |
Career history of David Altarac
Former positions of David Altarac
Companies | Position | Start | End |
---|---|---|---|
NeoStem, Inc. /Old/ | General Counsel | 30/06/2013 | 31/05/2015 |
SHIRE | Compliance Officer | 30/06/2015 | - |
General Counsel | 30/06/2015 | - | |
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | General Counsel | 27/01/2014 | - |
Training of David Altarac
New York University | Graduate Degree |
New York Medical College | Doctorate Degree |
State University of New York at Binghamton | Undergraduate Degree |
NYU Wagner | Graduate Degree |
Statistics
International
United States | 9 |
Ireland | 2 |
Operational
General Counsel | 3 |
Graduate Degree | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoral
Health Technology | 5 |
Consumer Services | 5 |
Transportation | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 5 |
---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
NeoStem, Inc. /Old/ | Transportation |
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- David Altarac
- Experience